CytomX Return On Equity from 2010 to 2024
| CTMX Stock | USD 1.59 0.01 0.63% |
Return On Equity | First Reported 2010-12-31 | Previous Quarter 0.01199233 | Current Value 0.0126 | Quarterly Volatility 0.75677729 |
Check CytomX Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CytomX main balance sheet or income statement drivers, such as Depreciation And Amortization of 2 M, Interest Expense of 2.1 M or Selling General Administrative of 28.8 M, as well as many exotic indicators such as Price To Sales Ratio of 1.07, Dividend Yield of 0.0299 or Days Sales Outstanding of 11.76. CytomX financial statements analysis is a perfect complement when working with CytomX Therapeutics Valuation or Volatility modules.
CytomX | Return On Equity |
Latest CytomX Therapeutics' Return On Equity Growth Pattern
Below is the plot of the Return On Equity of CytomX Therapeutics over the last few years. Return on Equity is the amount of CytomX Therapeutics net income returned as a percentage of CytomX Therapeutics equity. Return on equity measures CytomX Therapeutics profitability by revealing how much profit CytomX Therapeutics generates with the money shareholders have invested. It is a measure of the profitability of a business in relation to the equity, calculated by dividing net income by shareholder's equity. CytomX Therapeutics' Return On Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CytomX Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported -54.75 | 10 Years Trend |
|
Return On Equity |
| Timeline |
CytomX Return On Equity Regression Statistics
| Arithmetic Mean | (0.20) | |
| Coefficient Of Variation | (385.61) | |
| Mean Deviation | 0.60 | |
| Median | 0.01 | |
| Standard Deviation | 0.76 | |
| Sample Variance | 0.57 | |
| Range | 3.1349 | |
| R-Value | (0.25) | |
| Mean Square Error | 0.58 | |
| R-Squared | 0.06 | |
| Significance | 0.37 | |
| Slope | (0.04) | |
| Total Sum of Squares | 8.02 |
CytomX Return On Equity History
About CytomX Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include CytomX Therapeutics income statement, its balance sheet, and the statement of cash flows. CytomX Therapeutics investors use historical funamental indicators, such as CytomX Therapeutics's Return On Equity, to determine how well the company is positioned to perform in the future. Although CytomX Therapeutics investors may use each financial statement separately, they are all related. The changes in CytomX Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on CytomX Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on CytomX Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in CytomX Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Equity | 0.01 | 0.01 |
Pair Trading with CytomX Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CytomX Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CytomX Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with CytomX Stock
| 0.76 | A | Agilent Technologies Financial Report 28th of May 2024 | PairCorr |
| 0.81 | ELEV | Elevation Oncology Earnings Call This Week | PairCorr |
| 0.82 | ENVB | Enveric Biosciences Financial Report 20th of May 2024 | PairCorr |
The ability to find closely correlated positions to CytomX Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CytomX Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CytomX Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CytomX Therapeutics to buy it.
The correlation of CytomX Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CytomX Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CytomX Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CytomX Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of CytomX Therapeutics Correlation against competitors. For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Complementary Tools for CytomX Stock analysis
When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |
Is CytomX Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CytomX Therapeutics. If investors know CytomX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CytomX Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.01) | Revenue Per Share 1.371 | Quarterly Revenue Growth 0.322 | Return On Assets (0.02) | Return On Equity (54.75) |
The market value of CytomX Therapeutics is measured differently than its book value, which is the value of CytomX that is recorded on the company's balance sheet. Investors also form their own opinion of CytomX Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CytomX Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CytomX Therapeutics' market value can be influenced by many factors that don't directly affect CytomX Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CytomX Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CytomX Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CytomX Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.